Drugs / 2,3-dimercapto-1-propanesulfonic acid
Trials 2 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 01 trial | ||||||
| Phase 0 | NCT03957720 | Mar 2019 → Dec 2024 | Wilson disease | Second Affiliated Hospital, School of Medicine, Zhejiang University | Unknown | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT07500233 | Jan 2027 → Oct 2028 expected | snakebite envenomation | Liverpool School of Tropical Medicine | Not yet recruiting | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | 2,3-dimercapto-1-propanesulfonic acid | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07500233 ↗ |
| Known as | DMPS | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03957720 ↗ |
| Modality | Small molecule | — CHEMBL1624767 ↗ |
| Route | Oral | “Oral administration” NCT07500233 ↗ |